Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SLS. Li

Discussion

Loading...

Member takes

Overview

Retrospective cohort study compares venetoclax plus hypomethylating agents with intensive chemotherapy in AML-M5, suggesting inferior long-term outcomes with venetoclax.

Key Points

  • Similar complete remission rates were observed between venetoclax with hypomethylating agents and intensive chemotherapy in newly diagnosed acute monocytic leukemia patients.
  • The one-year disease-free survival was significantly inferior for the venetoclax group at 56.2% compared to 83.3% for the intensive chemotherapy group.
  • Retrospective cohort study utilized a comparison of treatment outcomes in 28 patients at one medical center from 2022 to 2024.
  • Higher relapse rates and lower long-term efficacy imply further studies are needed to refine induction strategies for this leukemia subtype.

Cite This Study

S. Li (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d32chttps://doi.org/10.1182/blood-2025-6976
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  2. 2Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  3. 3Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025
  4. 4Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience2025
  5. 5A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations